In 1980, Mr. Matthew Autterson graduated from Michigan University having gained a B.A in Finance then later attended University of Denver Graduate Tax Program. Matthew schooled at his hometown Michigan where he was born and raised. The skills he has been able to obtain made him president of one of the largest state-charted financial firm based in the country for the 25 years.
Mr. Matthew Autterson startup career was at First Trust Cooperation which happens to be a minor to Fiserv. In 1982 Matthew left the company to join a small team that saw to it the charter of a new Colorado State Charted Trust Company which a subsidiary of New York-based financial services firm is.
Matthew Autterson took the helm of Resources Trust Company as the president in 1986. In 1989 there were massive changes in the company which later resulted in AIG acquiring the assets of Resource Trust Company. The company started off by being acquired by Broad Inc. as all assets belonging to Integrated Resources Inc. were sold. AIG acquired broad Inc. which later became Sun America, Inc for 18 billion dollars in 1998.
The evolution of the company did not end there as in 2001; Resources Trust company was acquired from AIG by Fiserv. Resource Trust Company was able to be among the most significant state-chartered depository trust companies in the country before the sale. The company had more than 200,000 clients who have catered for depository and custodial services.
Mr. Autterson happens to be among the Board of Directors for Falci Adaptive Bio-systems. Matthew Autterson is also the leader of Colorado Business Community the FAB happens to demonstrate Autterson’s philanthropic interest after years of leadership roles he has been able to have as a member of the following boards Denver Zoo, Denver Zoological Foundation, Webb-Warring Foundation and the Denver Hospice where he was the chairman. Matthew Autterson happens to have been a member of the Young Presidents Association and also the World Presidents Association.
Matthew Autterson presently is in charge of a drug development company called CNS Bioscience, Inc established in 2013. The firm focuses on neuropathic pain as it develops its medicine. View More Information Here.